• Samsung Biologics raised its 2026 revenue forecast to KRW 5.47 trillion from KRW 5.32 trillion in an October 21 correction.
• The revised outlook targets 20% year-over-year growth, replacing the midpoint of a previous 15%-20% growth range.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung Biologics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261021800395), on October 21, 2026, and is solely responsible for the information contained therein.